Paper Details

  1. Home
  2. Paper Details

A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation.

Author: CarlensS, HägglundH, MattssonJ, OmanS, RembergerM, RingdénO

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A study comparing three different timing regimens for Filgrastim (r-metHuG-CSF) after unrelated bone marrow transplantation (BMT) found no significant differences in hematological recovery, complications, or survival. Starting Filgrastim treatment later (day +10) reduced costs without affecting recovery time.
Paper Details　
Original Abstract of the Article :
A study was done to compare treatment with Filgrastim (r-metHuG-CSF) given at three different times after unrelated bone marrow transplantation (BMT). Sixty-nine patients grafted with HLA-A, -B and -DR-compatible unrelated bone marrow were randomized to Filgrastim (5 microg/kg/day) starting on day 0...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/sj.bmt.1701996

データ提供：米国国立医学図書館（NLM）

Filgrastim Timing in Unrelated Bone Marrow Transplantation

This prospective randomized trial investigates the optimal timing for administering Filgrastim (r-metHuG-CSF) after unrelated bone marrow transplantation (BMT). The study enrolled 69 patients who received HLA-A, -B, and -DR-compatible unrelated bone marrow transplants and randomized them to receive Filgrastim starting on day 0, day +5, or day +10 after BMT. The researchers compared the hematological recovery, incidence of complications, and overall survival among the three groups.

Filgrastim Timing Doesn't Impact Recovery or Survival

The study found no significant differences in hematological recovery, incidence of fever, days on antibiotics, incidence of bacteremia, need for transfusions, or overall survival between the three groups. The time to reach an absolute neutrophil count (ANC) greater than 0.5 x 109/l was similar across groups, suggesting that the timing of Filgrastim administration did not significantly affect hematological recovery.

Optimizing Filgrastim Administration in BMT

This research provides valuable information for optimizing Filgrastim administration in unrelated BMT. The study's findings suggest that starting Filgrastim on day +10, rather than day 0, can reduce costs without compromising hematological recovery or overall survival. This information can help healthcare providers make informed decisions regarding Filgrastim administration in BMT, balancing effectiveness with cost considerations.

Dr. Camel's Conclusion

This research is like a compass guiding us through the complexities of bone marrow transplantation, helping us navigate the optimal timing for Filgrastim administration. The researchers found that starting Filgrastim on day +10 is a cost-effective approach without compromising patient outcomes. This study highlights the importance of carefully considering the timing of interventions in complex medical procedures, striving for optimal outcomes while balancing resources.

Date :
  1. Date Completed 1999-12-27
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

10516692

DOI: Digital Object Identifier

10.1038/sj.bmt.1701996

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.